

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

# Annual Summary Reporting Requirements Under the Right to Try Act

Docket No. FDA-2019-N-5553

Final Regulatory Impact Analysis  
Final Regulatory Flexibility Analysis  
Unfunded Mandates Reform Act Analysis

Economics Staff  
Office of Economics and Analysis  
Office of Policy, Legislation, and International Affairs  
Office of the Commissioner

## **Executive Summary**

This final rule establishes the deadline for submission of annual summaries of use of investigational drugs supplied under the Right to Try Act. The rule also establishes the required contents of these submissions. These reporting requirements instruct firms to collect all known serious adverse events and submit them once per year to FDA. In addition, based on the information in these annual summaries, FDA intends to post online an annual summary report in accordance with section 561B(d)(2) of the FD&C Act.

The benefits of this rule consist of societal and public health outcomes that may accrue from the disclosure of the use of investigational drugs and any known serious adverse events provided in these annual summary reports. There is no data that would allow us to predict the magnitude of generated benefits and thus we are unable to quantify the expected benefits of this rule.

Costs are estimated as the time spent by firms to prepare and submit these annual summary reports. The total estimated present value of this rule's costs is \$37,132 at a seven percent discount rate and \$45,818 at a three percent discount rate. The annualized cost of this rule over 10 years is \$5,287 at a seven percent discount rate and \$5,371 at a three percent discount rate.

## Table of Contents

Executive Summary .....	2
I. Introduction and Summary .....	4
A. Introduction.....	4
B. Summary of Costs and Benefits.....	4
C. Comments on the Preliminary Economic Analysis of Impacts and Our Responses..	6
D. Summary of Changes.....	6
II. Final Economic Analysis of Impacts .....	7
A. Background.....	7
B. Need for Federal Regulatory Action.....	7
C. Purpose of the Rule .....	7
D. Baseline Conditions .....	8
E. Benefits of the Rule.....	8
F. Costs of the Rule.....	8
G. Distributional Effects.....	10
H. International Effects.....	10
III. Final Small Entity Analysis .....	11

## **I. Introduction and Summary**

### **A. Introduction**

We have examined the impacts of the final rule under Executive Order 12866, Executive Order 13563, the Regulatory Flexibility Act (5 U.S.C. 601-612), and the Unfunded Mandates Reform Act of 1995 (Pub. L. 104-4). Executive Orders 12866 and 13563 direct us to assess all costs and benefits of available regulatory alternatives and, when regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety, and other advantages; distributive impacts; and equity). We believe that this final rule is not a significant regulatory action as defined by Executive Order 12866.

The Regulatory Flexibility Act requires us to analyze regulatory options that would minimize any significant impact of a rule on small entities. Because the effects are low in cost and minimally dispersed, we certify that the final rule will not have a significant economic impact on a substantial number of small entities.

The Unfunded Mandates Reform Act of 1995 (section 202(a)) requires us to prepare a written statement, which includes an assessment of anticipated costs and benefits, before proposing “any rule that includes any Federal mandate that may result in the expenditure by State, local, and tribal governments, in the aggregate, or by the private sector, of \$100,000,000 or more (adjusted annually for inflation) in any one year.” The current threshold after adjustment for inflation is \$158 million, using the most current (2020) Implicit Price Deflator for the Gross Domestic Product. This final rule would not result in an expenditure in any year that meets or exceeds this amount.

### **B. Summary of Costs and Benefits**

This final rule implements a statutory requirement in the Right to Try Act that sponsors and manufacturers who provide an eligible investigational drug under the Right to Try Act to eligible patients submit to the Food and Drug Administration (FDA) an annual summary of such use. The Right to Try Act requires FDA to specify by regulation the deadline and requires that submissions include certain information.

The benefits of this final rule consist of societal and public health outcomes that may accrue from the disclosure of the use of investigational drugs and any known serious adverse events provided in these annual summary reports. These reporting requirements instruct firms to collect all known serious adverse events and submit them once per year to the FDA. Without these reports, FDA would not be made aware in a systematic manner of the use of eligible drugs under the Right to Try Act and any known serious adverse events. With these reports, there may be increased awareness of investigational drugs, the diseases or conditions for which patients are seeking access, and any known serious adverse events associated with such use.

In addition, based on the information in these annual summaries, FDA intends to post an annual summary report in accordance with section 561B(d)(2) of the FD&C Act. FDA’s posting of these reports may increase awareness about the availability of investigational drugs. In some cases,

access to such drugs may help treat future patients. There is no data that would allow us to predict the magnitude of generated benefits and thus we are unable to quantify the expected benefits of this rule.

Costs are calculated as the time spent by firms to prepare and submit annual summary reports based on participation in Right to Try Act requests from eligible patients for investigational new treatments. The total estimated present value of this rule’s costs is \$37,132 at a seven percent discount rate and \$45,818 at a three percent discount rate (in 2020 dollars). The annualized cost of this rule over ten years is \$ \$5,287 at a seven percent discount rate and \$5,371 at a three percent discount rate. Consistent with Executive Order 12866, Table 1 provides the costs and a description of benefits for this final rule over a ten-year period.

**Table 1. Summary of Benefits, Costs, and Distributional Effects of Final Rule**

Category		Primary Estimate	Low Estimate	High Estimate	Units			Notes
					Year Dollars	Discount Rate	Period Covered	
Benefits	Annualized Monetized \$/year				2020	7%	10	
					2020	3%	10	
	Annualized Quantified					7%		
						3%		
Qualitative	Disclosure of serious adverse events and outcomes related to investigational new drug treatments.							
Costs	Annualized Monetized \$/year	\$5,287			2020	7%	10	
		\$5,371			2020	3%	10	
	Annualized Quantified					7%		
						3%		
Qualitative								
Transfers	Federal Annualized Monetized \$/year					7%		
						3%		
	From/ To	From:			To:			
	Other Annualized Monetized \$/year					7%		
						3%		
From/To	From:			To:				
Effects	State, Local or Tribal Government:							
	Small Business:							
	Wages:							
	Growth:							

### C. Comments on the Preliminary Economic Analysis of Impacts and Our Responses

FDA received less than 50 comments to the proposed rule from healthcare professionals, patient advocacy groups, regulated industry, scientific and academic experts, and private citizens. These comments and FDA's responses are summarized in the preamble to the final rule; there were no comments relating to the proposed regulatory impact analysis.

### D. Summary of Changes

Compared to the preliminary regulatory impact analysis, this analysis utilizes more recent wage data from 2020. For clarity, a summary table of total costs has been added to Section F. Costs of the Rule.

## **II. Final Economic Analysis of Impacts**

### **A. Background**

The Right to Try Act was signed into law in May 2018, creating section 561B of the Federal Food, Drug, and Cosmetic (FD&C) Act. This new law amends the FD&C Act to establish an option for patients who meet certain criteria to request access to certain unapproved medical products, and for sponsors and manufacturers who agree to provide certain unapproved medical products other than through FDA's expanded access program. The law establishes a new pathway for patients to request, and manufacturers or sponsors to choose to provide, access to certain unapproved, investigational treatments for patients diagnosed with life-threatening diseases or conditions who have exhausted approved treatment options and who are unable to participate in a clinical trial involving the investigational drug. The Right to Try Act is designed to facilitate patients' access to certain investigational drugs from manufacturers and sponsors who may choose to provide such drugs – a process in which FDA is not involved.

Manufacturers or sponsors who provide their investigational drug under the Right to Try Act are required to submit to FDA an annual summary of drugs supplied to eligible patients. Specifically, this annual summary must include the name of the investigational drug, the number of doses supplied, the number of patients treated, the uses for which the drug was made available, and any known serious adverse events. FDA is required to specify the deadline for such reporting submissions. This final rule will provide information on the necessary contents of the annual summary and the deadline for its submission.

### **B. Need for Federal Regulatory Action**

The Right to Try Act requires FDA to specify by regulation the deadline of submission of an annual summary of an eligible investigational drug supplied by manufacturers or sponsors to eligible patients. This rule would implement this provision of the Right to Try Act. This regulation would allow FDA to receive information about Right to Try Act access and activity, including any known serious adverse events. Requests for access under the Right to Try Act are not overseen by FDA. This rule would provide a mechanism for FDA to receive information about the use of drugs and adverse event data associated with the Right to Try Act in a systematic manner.

### **C. Purpose of the Rule**

The purpose of this final rule is to implement section 561B(d)(1) of the FD&C Act, as amended by the Right to Try Act, which requires sponsors and manufacturers who provide an eligible investigational drug under section 561B of the FD&C Act to submit to FDA an annual summary of such use and requires FDA to specify by regulation the deadline of submission. The rule would provide information on the necessary contents of the annual summary along with the deadline for its submission. Under this final rule, FDA would establish an email address or electronic portal for these submissions.

#### D. Baseline Conditions

This final rule is part of the implementation of the Right to Try Act, and so the baseline conditions refer to current conditions where the legislation has been enacted, but the rule not yet promulgated; thus, patients and physicians are currently able to determine eligibility, and drug sponsors are currently able to supply eligible investigational drugs under the Right to Try Act if they are willing to do so.

However, FDA has not yet specified by regulation the requirements for the content and the deadline for submission of an annual summary report. This regulation would affect any drug manufacturers or sponsors that provide an eligible investigational drug to eligible patients under the Right to Try Act. We assume these drug sponsors, when providing such eligible investigational new drugs to eligible patients, will have information on the number of doses that they supplied, the life-threatening disease for which the investigational drug was made available under the Right to Try Act, and known serious adverse events. The incremental burden drug sponsors may encounter from this regulation is the preparation and submission of the annual summary report described in the final rule based on information that was likely already collected.

#### E. Benefits of the Rule

The benefits of this final rule consist of societal and public health outcomes that may accrue from the disclosure of the use of investigational drugs and any known serious adverse events provided in these annual summary reports. Without these reports, FDA would not be made aware in a systematic manner of the use of eligible drugs under the Right to Try Act and any known serious adverse events. With these reports, there may be increased awareness of investigational drugs, the diseases or conditions for which patients are seeking access, and any known serious adverse events associated with such use.

These reporting requirements instruct firms to collect all known serious adverse events and submit them once per year to the FDA. In addition, based on the information in these annual summaries, FDA intends to post online an annual summary report in accordance with section 561B(d)(2) of the FD&C Act. FDA's posting of these reports may increase awareness about the availability of investigational drugs.

#### F. Costs of the Rule

This final rule implements a statutory requirement: the date of a submission of an annual summary report to be submitted by a drug manufacturer or sponsor providing an eligible investigational new drug to an eligible patient and includes the contents of the summary report. The incremental burden imposed by this rule will be in the form of costs associated with the drug sponsors' compilation and submission of these summary reports. This final rule is related only to the submission of the annual summaries and not to the Right to Try Act requests made by patients. The provisions are not necessarily expected to lead to additional Right to Try Act requests from patients. Thus, we do not expect that the final rule would lead to additional summaries and incremental cost burdens.

The Right to Try Act specifies the content of these annual summary reports. The drug sponsor's annual summary report would be required to include (1) the name of the investigational drug and applicable IND (investigational new drug) number, (2) number of doses supplied, (3) number of patients treated, (4) uses or conditions for which the drug was made available, and (5) any known serious adverse events or outcomes. The rule includes an example of a tabular summary that could be used for these data fields and report submission to FDA.

The purpose and attributes, along with the intended preparer, of this annual summary report are close to the information required in Form FDA 2252. Form FDA 2252 is required to accompany all annual report submissions regarding new information that might affect the safety, effectiveness, or labeling of a drug or biological product for human use. The sponsor of the drug or biological product is responsible for collecting the relevant information and submitting this form to the FDA. The time required to complete this form has been previously estimated by the FDA to average five hours; this includes time to review instructions, search and gather the existing data, and complete the information collection<sup>1</sup>. Because the final rule's tabular summary requires fewer required data elements (such as Field 8: Reporting Period in Form FDA 2252) and less summary information overall, we halve this time estimate to 2.5 hours.

We assume a medical director or regulatory affairs director will be responsible for preparing and submitting this annual summary report. The mean hourly wage (in 2020) for Medical and Health Services Managers in the Pharmaceutical and Medicine Manufacturing industry was \$98.78.<sup>2</sup> The total cost of labor is the fully-loaded wage, which includes overhead and benefits. We assume that the cost of overhead and benefits equals 100% of the wage, resulting in a fully-loaded total hourly wage of \$197.56. We estimate a cost of \$493.90 ( $=\$197.56 * 2.5$  hours) to prepare and submit each report.

Between passage of the Right to Try Act in May 2018 and January 2019, there were two publicly reported instances of patients who have received access to investigational treatments via the Right to Try Act pathway, though it is possible that there are other cases that have not been made public.<sup>3</sup> The annual summary report must include data for the preceding calendar year. For manufacturers or sponsors that have supplied eligible investigational drugs between the period of enactment and the date the final rule becomes effective, the first annual summary would be submitted 90 days after the rule becomes effective and would include all uses of eligible investigational drugs May 30, 2018 through the effective date of the final rule. Based on the two instances publicly reported

---

<sup>1</sup> This estimate for Form FDA 2252 has been reviewed and approved by the Office of Management and Budget. It was approved under OMB control number 0910-0001. See, Form FDA 2252 available at:

<https://www.fda.gov/media/73005/download>;

[https://www.reginfo.gov/public/do/PRAViewDocument?ref\\_nbr=201704-0910-006](https://www.reginfo.gov/public/do/PRAViewDocument?ref_nbr=201704-0910-006).

<sup>2</sup> Source: May 2020 National Industry-Specific Occupational Employment and Wage Estimates, U.S. Bureau of Labor Statistics. Available at: [https://www.bls.gov/oes/current/naics4\\_325400.htm](https://www.bls.gov/oes/current/naics4_325400.htm)

<sup>3</sup> See <https://med.nyu.edu/pophealth/divisions/medical-ethics/compassionate-use#Q21>

of so far, we estimate (and potentially overestimate) that there may be six summaries submitted by drug sponsors included in this initial group of reports.

With increasing awareness of the Right to Try Act pathway for access to investigational drugs without being part of clinical trials, the number of individual patients seeking access to such treatments may rise. There is uncertainty concerning the extent of this increase, however. There may be some increase in the years following passage of the Right to Try Act, which may at some point level off or even decline. Table 2 outlines our assumptions and estimates for the expected number of Right to Try Act annual summary reports submitted. The cost to prepare and submit each report, estimated above at \$493.90, is multiplied by the estimated number of annual reports we expect to receive over a ten-year period (six in year one, eight in year two, twelve in each subsequent year) to obtain the overall estimated costs of preparing and submitting these annual summary reports.

**Table 2. Estimated Number of Right to Try Act Annual Summary Reports**

Year After Passage of Right to Try Act	Expected Increase in Patient Requests and Annual Reports (%)	Expected Number of Annual Reports	Estimated Annual Costs (2020\$)
1	30	6	\$2,963
2	40	8	\$3,951
3	50	12	\$5,927
4	0	12	\$5,927
5 - 10	0	12	\$5,927

Table 3 below presents the total present value and annualized values over the ten-year period after the passage of the Right the Try Act. The total estimated present value of this rule’s costs is \$37,132 at a seven percent discount rate and \$45,818 at a three percent discount rate (in 2020 dollars). The annualized cost of this rule over ten years is \$ 5,287 at a seven percent discount rate and \$5,371 at a three percent discount rate.

**Table 3. Estimated Total Costs of the Final Rule (2020\$)**

	Present Value	Annualized Value
3% Discount Rate	\$45,818	\$5,371
7% Discount Rate	\$37,132	\$5,287

Note: Costs are estimated over a ten-year period.

#### G. Distributional Effects

We do not expect there to be any distributional effects of this rule. This final rule outlines the contents and deadline for an annual summary report submitted to FDA by drug sponsors and is not expected to generate any disproportionate impact on any specific industry or population group.

#### H. International Effects

We do not expect there to be any significant international effects of this rule. Both domestic and international drug sponsors would be subject to this annual summary reporting requirement.

### **III. Final Small Entity Analysis**

The Regulatory Flexibility Act requires Agencies to analyze regulatory options that would minimize any significant impact of a rule on small entities. Because the number of annual summary reports is anticipated to be relatively small (as a percentage of all investigational new drugs) and widely dispersed, we certify that the final rule will not have a significant economic impact on a substantial number of small entities. This analysis, as well as other sections in this document, serves as the Initial Regulatory Flexibility Analysis, as required under the Regulatory Flexibility Act.

We received no responses to our request for data on the number of small entities that would be affected by the rule nor data on the economic impact of the rule on these small entities.

The Small Business Administration defines an entity in the pharmaceutical industry as small if it has fewer than 1,250 employees. Based on this definition, about 90 percent of the drug entities are small. The impact on each entity will vary depending on its information collection capabilities when the rule is implemented, but all firms within this sector are familiar with the data and categories that comprise this annual summary report. The submission and data collection requirements are generally straight-forward and appropriate to the investigational new drug process.